LOGIN  |  REGISTER
Cue Biopharma
Recursion

CareDx To Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023 | Last Trade: US$16.95 0.16 -0.94

BRISBANE, Calif. / Aug 31, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference.

CareDx’s management is scheduled to present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 12:30 PM PT / 3:30 PM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s investor relations website at: investors.caredxinc.com.

About CareDx – The Transplant Company™

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page